Momcozy MaxSupport Nursing Pillow: Easier Nursing with Certified Safety and Ergonomic Design
New release aims to reduce strain, improve latching, and support healthier, more secure breastfeeding through certified-safe materials and an upgraded support structure.
New York, NY, May 30, 2025 (GLOBE NEWSWIRE) -- Momcozy, a global maternity care brand known for its innovation and dedication to maternal wellness, introduces the MaxSupport Nursing Pillow collection—an ergonomic, memory foam-based system designed to enhance comfort and safety for breastfeeding mothers. This launch is part of Momcozy's mission to make healthier, easier nursing a reality for every parent.Firm Support with Memory Foam Comfort
At the heart of every MaxSupport pillow is 45D high-density memory foam, selected for its ability to gently contour to the body while retaining structure. Unlike traditional fiber-filled pillows that lose shape over time, MaxSupport offers a resilient foundation that feels like resting on a mini high-quality mattress.
Its 28% wider surface provides enhanced arm and upper-body support—minimizing shoulder tension and promoting natural feeding alignment, especially during extended sessions.
Certified Safety That Meets 2024 Federal Standards
In response to the 2024 CPSC safety regulations, the MaxSupport Nursing Pillow is fully engineered to meet the latest U.S. federal safety standards. The pillow's certified firmness, safe feeding angles, and protective side barrier are designed to reduce the risks of suffocation and falls—giving moms peace of mind during every feeding.
All MaxSupport models are made with CertiPUR-US® certified memory foam and OEKO-TEX® certified fabrics, ensuring the materials are non-toxic, skin-friendly, and safe for babies and mothers alike.
Built-In Safety Features for Confident Nursing
A softly contoured side safety fence surrounds the nursing area to help secure the baby in place, reducing the chance of rolling or slipping. This, combined with the adjustable height options and removable waist and arm support cushions, allows for full customization based on body type, feeding position, or postpartum recovery needs.
These ergonomic enhancements are designed to reduce back and neck strain, support better latching, and help alleviate common breastfeeding discomforts like nipple soreness due to poor positioning.
Two Models, One Purpose: Better Breastfeeding Support
The MaxSupport collection includes two tailored versions:
Momcozy Original MaxSupport Nursing Pillow – Essential Set ($54.99)
CozyPro MaxSupport Nursing Pillow – Upgraded Set ($69.99)
The Essential Set features all core ergonomic and safety innovations, while the CozyPro version includes enhanced premium fabric finishes for moms seeking a touch of elevated comfort and style. Both models are built to retain their shape over time, making them ideal for long-term, daily use.
Designed by Moms, Backed by Experts
The MaxSupport line was developed through real insights from mothers and professional feedback from healthcare advisors. Whether used during cluster feeding, nighttime nursing, twin feeding, or bottle support, the pillows are crafted to adapt to real-life parenting scenarios.
Momcozy's thoughtful design ensures that support doesn't fade over time, but continues to deliver relief, alignment, and comfort through each stage of the breastfeeding journey.
Comfort Is Care: A Brand Mission in Action
The launch of the MaxSupport Nursing Pillow reflects Momcozy's broader commitment to supporting parents through intuitive, functional, and medically informed maternity products. Alongside its popular wearable breast pumps, maternity apparel, and wellness tools, MaxSupport underscores the brand's belief that comfort is a form of care—and every mother deserves both.
Exclusively available at momcozy.com, the MaxSupport Nursing Pillow is more than a feeding accessory—it's a trusted daily companion for healthier breastfeeding, safer positioning, and an all-around better experience.
#MomcozyMaxSupportNursingPillow #MaxSupportNursingPillow #CertifiedComfortForMomsAbout Momcozy
Momcozy is a global maternal care brand dedicated to enhancing the lives of mothers and babies through science-backed, comfort-focused solutions. From pregnancy to postpartum, Momcozy creates practical, emotionally attuned products designed to meet the real-world needs of modern parenting.
CONTACT: Anna Jiang Momcozy pr at momcozy.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
2 hours ago
- Business Upturn
Unplugged Performance to Showcase Tesla Builds at Electrify Expo – North America's Largest EV Festival
LOS ANGELES, June 20, 2025 (GLOBE NEWSWIRE) — Unplugged Performance, the world leader in Tesla-focused performance upgrades, is headed to Electrify Expo, North America's premier electric vehicle lifestyle event. Taking place this weekend June 21st & 22nd, Electrify Expo invites EV enthusiasts, media, and families for an immersive look at the future of electrification. Unplugged Performance will be displaying four of its latest builds at the show, each with upgrades tailored for parts performance, durability, and everyday driving. Advertisement Tesla Model 3 Performance 'Red Rocket' Track Build Built to dominate the track and the streets, car features our: UP Race Pro Coilovers with Adaptive Canceller UP Carbon Fiber Front Aero Kit + Rear Dual Spoiler and Wing Set Up + Rear Spats and Diffuser 18×10.9 UP-03 Forged Wheels Yokohama ADVAN A052 295/35R18 Tires Satin Red 2026 Tesla Model Y Off-Road/Street Build Adventure-ready, this MY build includes our: UP 35mm Leveling Lift Kit Off-Road Spec 18″ UP-05 Forged Wheels Off-Road Sway Bar + End Links Yokohama GEOLANDAR Tires UP INVINCIBLE® Cybertruck Street Build The ultimate Tesla Cybertruck to take on anything on earth and beyond with: HD Front & Rear Bumpers, Bull Bar, Rock Sliders Carbon Fiber Hood w/ 50' LED Light Bar Side Sail Panel MOLLE Rack System 22' CYBRHEX Forged Wheels Yokohama GEOLANDAR Tires Quicksilver 2026 Tesla Model Y Off-Road/Street Build Ready for the streets, this MY build includes our: 22' UP Forged CYBRHEX Wheels Moderate option Dual Rate Lowering Springs Yokohama Parada Spex-X Tires Learn more about our products at Media Contact: Bryan Benitez [email protected] Photos accompanying this announcement are available at: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Upturn
2 hours ago
- Business Upturn
ImpactLife shares highlights from World Sickle Cell Disease Awareness Day event
Davenport, Iowa, June 20, 2025 (GLOBE NEWSWIRE) — ImpactLife hosted a special event at its Davenport, Iowa headquarters to recognize World Sickle Cell Disease Awareness Day as part of local celebrations of the Juneteenth federal holiday. The Juneteenth holiday — commemorating the emancipation of enslaved people in the United States — is also recognized as World Sickle Cell Awareness Day with the goal to increase public knowledge of sickle cell disease and the challenges experienced by patients and caregivers. Community members and blood center employees gathered on Thursday, June 19, to learn about the importance of blood transfusions in providing supportive care for sickle cell patients and to hear personal experiences from those who live with sickle cell disease, or who have lost loved ones to the genetically inherited blood disorder. Speakers included Beleta Rush, who shared writings and experiences from the lives of her two daughters, Lynn and Bobbie. View and download video clips from the event, below, or on the ImpactLife web site. Dr. Meredith Parsons, Clinical Assistant Professor of Pathology from University of Iowa, provided an overview on sickle cell disease, how it affects patients, and the importance of having appropriately matched units of blood available for patients who are likely to receive multiple rounds of blood transfusions throughout their lives. Shyneeta Rush, Supervisor, Donor Services, described the blood center's Red4Life program and efforts by the blood center to identify donors who are an appropriate match for sickle cell disease patients. Cheryl Easley, of the ImpactLife donor scheduling team, helped organize the event, and recognized sickle cell 'Warriors In Battle' as well as 'Winged Warriors,' who have passed after living with the disease throughout their lives. Lamour Bluitt has two sisters living with sickle cell disease, and has authored a book on their experiences, A Child Born with Sickle Cell: the Untold Secret. About Sickle Cell Disease Sickle dell disease is an inherited blood disorder that affects red blood cells. It is the most common hereditary disorder and currently affects more than 100,000 Americans, predominantly people of African descent. The red blood cells in patients with sickle cell disease can become 'sickled' in shape, which can cause the cells to become stuck in small blood vessels. Patients can experience pain and anemia and are at increased risk for strokes and other types of organ damage. When patients experience a sickle cell crisis, red cell transfusion is a major form of therapy to relieve symptoms. Patients with sickle cell disease frequently receive transfusions of red blood cells to help treat symptoms of a sickle cell crisis. But finding appropriately matched units for sickle cell disease patients is a challenge for blood providers. With more frequent blood transfusions, patients with sickle cell disease can develop antibodies that are directed against red blood cell antigens. This process, called alloimmunization, makes it important for patients to receive antigen-negative blood types that are more generally found in donors of African descent. To help increase the diversity of the blood center's donor base, ImpactLife has created a donor program called Red4Life. Under Red4Life, the blood center identifies and recruits donors who may be an appropriate antigen match for patients with sickle cell disease. These donors are then invited to join the Red4Life program and receive special donor rewards and additional points to use in the ImpactLife Donor Loyalty Store. (Learn more at About ImpactLife ImpactLife's mission is to save lives by engaging donors, supporting partners, and advancing medicine. Founded in 1974, ImpactLife supplies blood products and services to hundreds of hospitals, emergency services organizations, clinical researchers, and other blood centers throughout Iowa, Illinois, Wisconsin, and Missouri. The nonprofit blood provider is ranked among the leading 12 blood suppliers in the United States. For more information on current blood inventory levels, our donor promotions, and more, see and find us @impactlifeblood on Facebook, X, Instagram, Threads, YouTube, and LinkedIn. Attachments Beleta Rush ImpactLife – World Sickle Cell Disease Awareness Day group photo Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
